Whereas intraventricular injection of amyloid does not alter CCK mRNA levels in the hippocampus (Aguado-Llera et al., 2018), and the number of CCK INs in CA1 (in SO) remained unchanged with intrahippocampal injection of amyloid (Villette et al., 2012), APP/PS1 mice feature a reduction of CB1R-expressing CCK interneurons in DG and CA1 (He et al., 2021). The gene discussed is APP; the disease is amyloidosis.